Oppenheimer Would Be Buyers of Relay Therapeutics (RLAY) Ahead of AACR
Tweet Send to a Friend
Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $33.00 price target on Relay Therapeutics (NASDAQ: RLAY), saying they would ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
